MedTrace Logo

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

NCT03289702 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2021-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity

Conditions

  • Muscle Spasticity

Interventions

DRUG

CORETOX®

Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

DRUG

BOTOX®

Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-13
Primary Completion
2018-06-30
Completion
2018-11-09

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289702 on ClinicalTrials.gov